| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5603e41a102405f80fbd4eb0b3491905 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-1468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01B23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2015-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7105fea4884fd93810167671ae8b74b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0cb2b5eeec56901c0af86c7272be0b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9350ca3d4d9b00eb98583f0e158c82d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28649430a3b57d8002c01c827732fbbd |
| publicationDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018228729-A1 |
| titleOfInvention |
Method for preparing ophthalmic preparation containing thymosin beta-4 |
| abstract |
The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin β4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin β4 is carried out in the presence of an inert gas, thus the contact of thymosin β4 with oxygen is blocked and the oxidation of thymosin β4 can be prevented and the pharmacological activity of thymosin β4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin β4 in a stable state for a long time. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112107678-A |
| priorityDate |
2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |